

Sponsor:	IO Biotech ApS
Protocol Number:	IO102-012
EudraCT Number:	2018-000139-28
Date of Clinical Study Report:	19 May 2023

The following table has been extracted from the final IO102-012 Clinical Study Report (dated 19 May 2023) and presents a summary of the Time to First Subsequent Treatment or Death (TFST).

Secondary Endpoint: Time from First Treatment to the Commencement of First Subsequent Treatment or Death – Both Phases

Number of Patients (ITT Population)	Cohort A		Cohort B	
	Exp A1 ^[1] N=38	Control A2 ^[2] N=16	Exp B1 ^[3] N=39	Control B2 ^[3] N=17
No. of TFST events	28 (73.7%)	11 (68.8%)	33 (84.6%)	14 (82.4%)
Median months to event And 95% CI	10.3 [5.3 ; 19.8]	7.0 [4.8 ; 17]	11.8 [9.0 ; 14.7]	10.7 [7.2 ; 19]

[1] Exp A1 = Arm A (Phase I) + Arm A1 (Phase II)

[2] Control A2 = Arm A2 (Phase II)

[3] Exp B1 = Arm B (Phase I) + Arm B1 (Phase II)

[4] Control B2 = Arm B2 (Phase II)